Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Diabetes Care Devices Market is predicted to reach US$ ~32,255.9 million by 2031 from US$ ~68,733.5 million in 2020, and to grow at a CAGR of ~8.3% between the forecast period 2021 to 2031.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2021 to 2031. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2020. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
Type (Insulin Delivery Devices, Self-Blood Glucose Monitors, and Continuous Glucose Monitoring Devices], End User [Homecare, Hospitals & Clinics, and Diabetes Specialty Centers]
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
Abbott, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Becton, Dickinson & Company (Embecta Corp.), Terumo Corporation, B. Braun Melsungen AG, Medtronic, ARKRAY USA, Inc., ACON Laboratories, Inc., Dexcom Inc., Tandem Diabetes Care, Ypsomed Holding AG Inc., Eli Lilly and Company, Ascensia Diabetes Care Holdings AG, and LifeScan, Inc.